PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ:CYTO) today announced that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has initiated a randomized Phase 2 study to evaluate QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with the NIH’s targeted therapeutic vaccine, PSA-TRICOM, for patients with progressive hormone-refractory prostate cancer who have failed docetaxel-based regimens.
